礼来公司的每周使用一次的胰岛素 efsitora alfa 在 2 型糖尿病患者中达到了非劣效的 A1C 降低效果。 Eli Lilly's once-weekly insulin, efsitora alfa, met non-inferior A1C reduction in type 2 diabetes patients.

礼来公司的每周一次的胰岛素 efsitora alfa 在两项 3 期临床试验中达到了主要终点，证明在 2 型糖尿病患者中 A1C 降低效果不逊于其他药物。 Eli Lilly's once-weekly insulin, efsitora alfa, met the primary endpoint in two phase 3 clinical trials, demonstrating non-inferior A1C reduction in type 2 diabetes patients. 结果表明，efsitora 与每日胰岛素治疗一样有效。 The results show that efsitora is as effective as daily insulin treatments. 该研究结果领先于诺和诺德每周一次的胰岛素竞争对手icodec，后者正在接受美国食品和药物管理局内分泌和代谢药物咨询委员会的审查。 The study results come ahead of Novo Nordisk's once-weekly competitor, insulin icodec, being reviewed by the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee.